NexImmune, Inc. (NASDAQ: NEXI - Get Free Report)'s share price shot up 2,169,900% during mid-day trading on Tuesday. The stock traded as high as $2.17 and last traded at $2.17. 12,837 shares changed hands during trading, an increase of 176% from the average session volume of 4,645 shares. The stock had previously closed at $0.0001.

Profitability This table compares NexImmune and Avenue Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NexImmune N/A -534.32% -213.72% Avenue Therapeutics N/A -471.57% -296.50% Volatility and Risk NexImmune has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P

Earnings and Valuation This table compares NexImmune and IMV"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A IMV $330,000.00 0.00 -$37.99 million ($4.59) N/A NexImmune has higher earnings, but lower revenue than IMV. Risk and Volatility NexImmune has

Palatin Technologies (PINK: PTNT - Get Free Report) and NexImmune (NASDAQ: NEXI - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation. Analyst Recommendations This is a summary of recent ratings

Valuation and Earnings This table compares NexImmune and Evotec"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A Evotec $572.16 million 1.71 $7.14 million $0.41 7.24 Evotec has higher revenue and earnings than NexImmune. NexImmune is trading at a

Profitability This table compares eFFECTOR Therapeutics and NexImmune's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A NexImmune N/A -534.32% -213.72% Institutional and Insider Ownership 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned

NexImmune (NASDAQ: NEXI ) stock is no longer trading on the Nasdaq Exchange after the company's shares were delisted on Friday morning. This saw shares of NEXI stock removed from the Nasdaq Exchange when markets opened this morning.

Embattled biotechnology firm NexImmune (NASDAQ: NEXI ) is seeing shares skyrocket on Thursday, possibly due to anticipation around a lingering business matter. Due to severe financial struggles, management has sought to dissolve the enterprise.

GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.